ARCH Venture Fund IX, L.P. sold $40K of BOLD (indirect holdings)

ARCH Venture Fund IX, L.P. sold 16,000 indirectly-held shares of Boundless Bio, Inc. (BOLD) at $2.49 on 2026-07-01.

Original reporting
SEC EDGAR · ARCH Venture Fund IX, L.P.
Published Jul 6, 2026, 9:43 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 6, 2026, 9:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BOLD
Neutral
medium confidence
Mentioned
$BOLD
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BOLDNeutralLow
01

Why it matters

Traders may monitor for follow-on selling or changes in ownership, but this text alone does not indicate a broader negative development.

02

Market read

A disclosed owner sale at a specific price and date, with holdings reduced to zero, but no accompanying fundamental news.

03

What to watch

Indirect holdings and a single sale lot may reflect diversification/liquidity needs rather than a view on valuation or prospects.

Relevance 3/10Novelty 3/10Timing: Filed 2026-07-06 after-hours; reflects sale executed 2026-07-01.

Background

The filing is a SEC Form 4 insider transaction for Boundless Bio, Inc., reported by a 10% owner via indirect holdings.

Company-level read

Ticker impact

$BOLDNeutralMedium confidence
Context

ARCH Venture Fund IX, L.P. (10% owner) filed a Form 4 showing an open-market sale of 16,000 BOLD shares at $2.49 on 2026-07-01.

Expected impact

Likely limited near-term impact; any effect would be sentiment-only rather than a change in company fundamentals.

Evidence & confidence

Form 4 discloses the transaction details, but the article provides no new operational, financial, or regulatory information—only an ownership reduction.

Market effects

No sector read-through; this is a single-issuer Form 4 sale.

None indicated.

None indicated.

Counterpoint

The absence of a 10b5-1 plan could raise scrutiny, but the filing still lacks any evidence of distress or new negative information.

Key entities

  • Boundless Bio, Inc.

    Subject of the Form 4; transaction reported for BOLD shares.

  • ARCH Venture Fund IX, L.P.

    Reporter of the Form 4; sold 16,000 shares open-market at $2.49.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BOLDMed

Boundless Bio 3Q 2026: EPS ($0.23) — 10-Q Summary

Boundless Bio reported a 61.4% narrower net loss of $5.36M in Q3 2026, with EPS at ($0.23). The reduction was driven by lower clinical-trial spending, reduced facilities, and personnel costs. The company also announced a 75% workforce reduction and expects a merger with Serapha Bio to close in Q4 2026, with a pre-closing dividend of $44M-$48M.